Bloomberg Amgen Inc.’s new cholesterol drug is still struggling to gain traction, missing analysts’ estimates at a time when the biotechnology giant is anxious for its newer drugs to make up for slowing sales of its older ones. Sales of the drug, called Repatha, in the first quarter were $49 million, the company said in a statement. That was ...
Read More »